HANGZHOU, China, June 06, 2021 (GLOBE NEWSWIRE) — AnHeart Therapeutics Co., Ltd (AnHeart), a clinical stage oncology company focused on underserved patients in global markets, together with Innovent Biologics, Inc. (Innovent, HKEX: 01801), today jointly announce a presentation of a scientific poster entitled Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer (NSCLC) which summarizes initial…

Click here to view the original article.